Are lorcaserin and phentermine plus extended-release topiramate safe and effective for weight loss?
Metadata[+] Show full item record
The FDA recently approved the use of a new selective serotonin 2C (5-HT2C) receptor agonist, lorcaserin (Belviq®), and a new fixed-dose combination of the sympathomimetic amine phentermine and an extended-release form of the antiepileptic drug topiramate (Qsymia®), as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults. Both are indicated in patients who have a body mass index (BMI) ≥30 kg/m2 or who are overweight (BMI ≥27 kg/m2) with at least 1 weight-related comorbidity.
Evidence Based Practice 16(8): 13-14.